

# Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021

<https://marketpublishers.com/r/MF9168095F4DEN.html>

Date: October 2021

Pages: 82

Price: US\$ 3,500.00 (Single User License)

ID: MF9168095F4DEN

## Abstracts

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021

### SUMMARY

According to the recently published report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2021'; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.

The report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2021' outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and

dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Ophthalmology which include indications Anxiety Disorders, Depression, Fragile X Syndrome, Alzheimer's Disease, Autism, Blepharospasm, Drug-Induced Dyskinesia, Major Depressive Disorder, Parkinson's Disease, Schizophrenia, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Dementia, Drug Addiction, Dyskinesia, Dystonia, Movement Disorders, Neurology, Pain, Seizures, Spasmodic Torticollis (Cervical Dystonia), Substance (Drug) Abuse and Trigeminal Neuralgia (Tic Douloureux).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of

administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies

Involved in Therapeutics Development

Addex Therapeutics Ltd

Allos Pharma Inc

Allyx Therapeutics Inc

Bristol-Myers Squibb Co

Hua Medicine Shanghai Ltd

Laboratorio Farmaceutico CT Srl

Lactocore Inc

Noema Pharma AG

Novartis AG

Park Active Molecules

Richter Gedeon Nyrt

Tempero Bio

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles

alloswitch-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-952048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0014242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCGM-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOE-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0431316 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 5 (GPCR1E or MGLUR5 or GRM5) - Dormant Products

Metabotropic Glutamate Receptor 5 (GPCR1E or MGLUR5 or GRM5) - Discontinued Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones

Featured News & Press Releases

Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in blepharospasm

Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson's Disease

May 17, 2021: Addex's Dipraglurant restores synaptic plasticity in models of Dystonia

Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results

Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome

Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders

Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share

Feb 06, 2017: Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases

Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

Jan 04, 2016: Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indications, 2021  
Number of Products under Development by Indications, 2021 (Contd..1)  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Addex Therapeutics Ltd, 2021  
Pipeline by Allos Pharma Inc, 2021  
Pipeline by Allyx Therapeutics Inc, 2021  
Pipeline by Bristol-Myers Squibb Co, 2021  
Pipeline by Hua Medicine Shanghai Ltd, 2021  
Pipeline by Laboratorio Farmaceutico CT Srl, 2021  
Pipeline by Lactocore Inc, 2021  
Pipeline by Noema Pharma AG, 2021  
Pipeline by Novartis AG, 2021  
Pipeline by Park Active Molecules, 2021  
Pipeline by Richter Gedeon Nyrt, 2021  
Pipeline by Tempero Bio, 2021  
Dormant Products, 2021  
Dormant Products, 2021 (Contd..1)  
Dormant Products, 2021 (Contd..2)  
Discontinued Products, 2021  
Discontinued Products, 2021 (Contd..1)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/MF9168095F4DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF9168095F4DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

